This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Dr. Parmis Mojarab, DO·Published July 12, 2026·Last reviewed August 4, 2026·Methodology v1.0

This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

Mounjaro: what it is, cost and alternatives

Quick answer

Mounjaro is the brand name for tirzepatide — a dual gip / glp-1 receptor agonist — FDA-approved for type 2 diabetes. Typical cost: As low as $25/month with commercial insurance and the savings card, but Lilly runs NO self-pay programme for Mounjaro at weight-loss doses. Cash-pay patients who want tirzepatide should look at Zepbound — the identical molecule — via LillyDirect at $299-$449.. Because it shares an active ingredient with other brands and with compounded preparations, patients often compare pathways on price and access.

The $449 tier has a condition. LillyDirect prices Zepbound at $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg) a month under its self-pay programme. The $449 rate on 7.5 mg and above holds only if you refill within 45 days of your previous delivery. Miss that window and the refill is charged at the standard rate — reported at $499 to $699 depending on dose — before the programme rate resumes on the next order. Re-read at source 4 August 2026.

What is Mounjaro, and who is it for?

Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates two incretin receptors rather than one. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. In the pivotal SURMOUNT-1 trial, the highest dose produced about 20.9% average body-weight reduction over 72 weeks.

For the molecule-level detail — mechanism, trial evidence, side effects and warnings — see our full tirzepatide guide.

What does Mounjaro cost?

As low as $25/month with commercial insurance and the savings card, but Lilly runs NO self-pay programme for Mounjaro at weight-loss doses. Cash-pay patients who want tirzepatide should look at Zepbound — the identical molecule — via LillyDirect at $299-$449.

The Mounjaro cash-pay trapDo not buy Mounjaro with cash for weight loss. Mounjaro and Zepbound are the same molecule (tirzepatide). Lilly runs a self-pay programme for Zepbound but not for Mounjaro, so cash-pay Mounjaro through telehealth runs near retail while Zepbound costs $299-$449 through LillyDirect. Mounjaro makes financial sense only if your insurance covers it, which generally requires a type 2 diabetes diagnosis.

Our GLP-1 cost guide normalizes every cash and insured pathway side by side.

What are the alternatives to Mounjaro?

Depending on eligibility and budget, patients weigh other brand GLP-1 drugs, compounded preparations where lawfully available, and lifestyle-plus-clinical programs. Compare options in our best GLP-1 programs ranking and most affordable compounded tirzepatide guide.

Frequently asked questions

What is Mounjaro used for?

Mounjaro is FDA-approved for type 2 diabetes. Its active ingredient is tirzepatide.

How much does Mounjaro cost?

What is the difference between Mounjaro and compounded tirzepatide?

Mounjaro is an FDA-approved finished drug. Compounded tirzepatide is prepared by a pharmacy, is not FDA-approved, and its routine compounding is now restricted. See our compounded tirzepatide guide.

Sources

U.S. Food and Drug Administration — Mounjaro prescribing information and label.
Manufacturer pricing and savings program pages (verify current terms).
Our normalized cost analysis, prices verified August 4, 2026.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices — NovoCare and LillyDirect — were re-read on the manufacturers’ own published price guides on 4 August 2026. Figures captured from third-party provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row says so. We do not restamp a figure we have not re-read.